The paper with the title "Determination of the therapeutic effect of the intravitreal administration of autologous adipose derived-mesenchymal stromal cells combined with anti-VEGF nanocarriers, in an animal model of induced retinal vein occlusion" was recently published in Cytotherapy, as the result of the ongoing collaboration of BikiarisLab with the Biohellenika Biotechnology Company and the School of Medicine of AUTH.
Background & Aim
In recent years, anti-angiogenic therapeutic agents (anti-VEGF) have contributed to the treatment of retinal vein occlusion (RVO). At the same time, Mesenchymal Stromal Cells-mediated therapies (MSCs) are associated with secretory agents that protect the ganglion cells, limiting eye degeneration. The aim of the present study is to encapsulate anti-VEGF in thiolated chitosan nanocarriers (nanoThioCHI) and to determine the effect of their combination with rabbit adipose tissue MSCs (ASCs) in a MEK inhibitor-PD0325901-mediated induced animal model of RVO.
Our lab was responsible for the encapsulation of anti-VEGF in thiolated chitosan nanocarriers. To read the full-text, click here.